Patents by Inventor Koichi Yanaba
Koichi Yanaba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295562Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.Type: ApplicationFiled: February 7, 2023Publication date: September 21, 2023Inventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
-
Publication number: 20190136185Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.Type: ApplicationFiled: November 19, 2018Publication date: May 9, 2019Applicant: Duke UniversityInventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
-
Patent number: 10131875Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.Type: GrantFiled: August 4, 2011Date of Patent: November 20, 2018Assignee: Duke UniversityInventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
-
Patent number: 9913863Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of these IL-10 producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.Type: GrantFiled: May 26, 2016Date of Patent: March 13, 2018Assignee: Duke UniversityInventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
-
Patent number: 9669057Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-IO). The invention also relates to the use of these IL-IO producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-IO production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.Type: GrantFiled: April 27, 2009Date of Patent: June 6, 2017Assignee: Duke UniversityInventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
-
Publication number: 20160375059Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of these IL-10 producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.Type: ApplicationFiled: May 26, 2016Publication date: December 29, 2016Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
-
Publication number: 20130136754Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.Type: ApplicationFiled: August 4, 2011Publication date: May 30, 2013Inventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
-
Publication number: 20110135666Abstract: The present invention relates to a phenotypically distinct CD1dhigh CD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-IO). The invention also relates to the use of these IL-IO producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-IO production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.Type: ApplicationFiled: April 27, 2009Publication date: June 9, 2011Inventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz